×
ADVERTISEMENT

AstraZeneca/Acerta Pharma

Acalabrutinib Granted Breakthrough Therapy Designation for MCL

Acalabrutinib was granted breakthrough therapy designation for treatment of patients with mantle cell lymphoma ...

AUGUST 2, 2017

Load more